People with ulcerative colitis, a form of IBD, who were taking the new drug Omvoh and achieved clinical remission after 1 ...

A once-daily pill for ulcerative colitis has delivered strong results in a clinical trial, easing symptoms even in patients ...

Once-daily oral obefazimod met the primary endpoint of clinical remission at 8 weeks in a highly refractory population of ...

The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative colitis who weigh ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...

Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ...

A multicenter trial from the Netherlands suggests that meticulous donor selection and anaerobic stool preparation may enhance ...

Eli Lilly’s ulcerative colitis (UC) treatment, Omvoh (mirikizumab), has shown sustained positive outcomes in patients with ...

While an individualized approach is best, these foods may support gut health in people with ulcerative colitis.

A 29-year-old man undergoes a total proctocolectomy with end-to-end ileostomy after 2 years of surveillance for ulcerative colitis.

The Food and Drug Administration (FDA) has expanded the approval of Simponi ® (golimumab) to include pediatric patients weighing at least 15kg with moderate to severely active ulcerative colitis (UC).

Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary ...